91 Noninvasive CT imaging biomarker to predict immunotherapy response in gastric cancer: an multicenter study

Yuming Jiang, Weicai HuangRegular 2023 · DOI

Introduction

Gastric cancer (GC) remains a significant global health challenge, but the advent of immune checkpoint inhibitors (ICIs)—specifically anti-PD-1/PD-L1 therapies—has offered a new lifeline for patients with advanced disease. However, the clinical reality is complex: while some patients experience remarkable long-term benefits, others derive no advantage, often facing unnecessary side effects and high treatment costs.

Existing biomarkers, such as PD-L1 expression or tumor mutational burden (TMB), are frequently used but remain imperfect. They often require invasive biopsies that may not capture the full spatial heterogeneity of the tumor. This study introduces a noninvasive alternative: a CT-based radiomics biomarker designed to predict immunotherapy response and progression-free survival (PFS) by analyzing the tumor and its immediate environment.

The Radiomics Approach

Radiomics is an emerging field that extracts high-dimensional quantitative features from medical imaging, such as CT scans, which are already a standard part of cancer care. Unlike traditional visual assessment by a radiologist, radiomics uses data-characterization algorithms to identify patterns in texture, shape, and intensity that are invisible to the human eye.

In this multicenter study, researchers analyzed 294 GC patients across three independent medical centers. The team focused on two distinct areas:

  1. Intratumoral Features: Characteristics within the tumor mass itself.
  2. Peritumoral Features: Characteristics of the tissue immediately surrounding the tumor.

By narrowing down an initial pool of data to 13 key CT features, the researchers developed a Radiomics Score (RS). This score was designed to predict immunotherapy-related progression-free survival (irPFS), providing a digital signature of the tumor's likely behavior under treatment.

Validating the Radiomics Score

To ensure the RS was robust and generalizable, the study utilized a rigorous validation framework across multiple cohorts:

  • Predictive Accuracy: The model achieved high 12-month Area Under the Curve (AUC) values, ranging from 0.787 in the training cohort to 0.810 and 0.785 in validation cohorts.
  • Long-term Reliability: In an external validation cohort, the 24-month AUC remained strong at 0.805, suggesting the score's predictive power is durable over time.
  • Survival Stratification: Patients were categorized into high and low RS groups. Those with a low RS demonstrated significantly longer irPFS across all cohorts, confirming that the score effectively identifies patients most likely to benefit from ICIs.

A critical component of this research was validating the biological "why" behind the imaging data. By linking the RS to bulk RNA sequencing data from The Cancer Genome Atlas (TCGA), the researchers discovered that the CT imaging biomarker was significantly associated with the infiltration of M1 macrophages.

In the tumor microenvironment, M1 macrophages are generally considered pro-inflammatory and anti-tumor, helping the immune system attack cancer cells. The correlation between a low RS and M1 macrophage presence suggests that the CT scan is effectively "seeing" a more favorable immune landscape, explaining why these patients respond better to immunotherapy.

Clinical Application: The Nomogram

To translate these findings into a tool for daily clinical use, the researchers developed a nomogram. This graphical tool integrates the RS with standard clinical characteristics. The resulting model achieved a C-index (concordance index) of 0.687–0.778, outperforming clinical factors alone. This provides oncologists with a more comprehensive, noninvasive method to estimate a patient's prognosis before starting therapy.

Conclusion and Future Directions

This study demonstrates that a noninvasive CT-based radiomics score can effectively predict immunotherapy outcomes in gastric cancer patients. By capturing the nuances of both the tumor and the peritumoral environment, the RS serves as a surrogate for the innate immune system's activity.

While the results are promising, the researchers note that future work should focus on prospective clinical trials to confirm these findings in real-time. Additionally, further standardization of radiomics features across different CT scanner technologies will be essential for widespread clinical adoption. Nonetheless, this imaging biomarker represents a significant step toward personalized, precision immunotherapy for gastric cancer.

Summary updated

Abstract

<h3>Background</h3> Despite remarkable benefit has been provided by immune checkpoint inhibitors in gastric cancer (GC), predictions of treatment response and prognosis remain unsatisfying, making identifying biomarkers desirable. We aim to develop and validate a CT imaging biomarker to predict the immunotherapy response in patients with GC and investigate the associated immune infiltration patterns. <h3>Methods</h3> This retrospective study includes 294 GC patients who received anti-PD-1/PD-L1 immunotherapy from three independent medical centers between January 2017 to April 2022. A radiomics score (RS) was developed from the intratumoral and peritumoral features on pretreatment CT images to predict immunotherapy related progression-free survival (irPFS). The performance of the RS was evaluated by the area under the time-dependent receiver operating characteristics curve (AUC). Multivariable Cox regression analysis was performed to construct predictive nomogram of irPFS. C-index were used to determine the performance of nomogram. Bulk RNA sequencing of tumors in The Cancer Genome Atlas was used to investigate the RS-associated immune infiltration patterns. <h3>Results</h3> Overall, 89 of 294 patients (median age, 57 years [IQR, 48–66 years]; 171 men) had objective response to immunotherapy. The RS included 13 CT features yielded 12-month AUCs of 0.787, 0.810 and 0.785 in training, internal validation, and external validation 1 cohorts, respectively, and 24-month AUC of 0.805 in external validation 2 cohort. Patients with low RS had longer irPFS in each cohort (P &lt; 0.05). Multivariable Cox regression analyses showed RS is the independent prognostic factor of irPFS. Nomogram that integrated RS and clinical characteristic showed improved performance in predicting irPFS with C-index of 0.687–0.778 in training and validation cohorts. The CT imaging biomarker was associated with M1 macrophages cells infiltration. <h3>Conclusions</h3> Noninvasive CT imaging biomarker can effectively predict immunotherapy outcomes in GC patients and is associated with innate immune system. <h3>Acknowledgements</h3> We acknowledge the TCGA database for providing their platforms and contributors for uploading their meaningful datasets. <h3>Ethics Approval</h3> Ethical approval was obtained from the institutional review board of the three participating centers, and informed consent was waived for this retrospective analysis.
BibTeX
@inproceedings{jiang2023noninvasive,
  author = {Yuming Jiang and Weicai Huang},
  title = {{91 Noninvasive CT imaging biomarker to predict immunotherapy response in gastric cancer: an multicenter study}},
  booktitle = {Regular},
  year = {2023},
  doi = {10.1136/jitc-2023-sitc2023.0091},
}
Figure